Skip Navigation

JNCI Journal of the National Cancer Institute 2009 101(4):215; doi:10.1093/jnci/djp010
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2009.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Potential Surrogate Endpoints for Prostate Cancer Survival

Clinical trials for prostate cancer that use surro-gate endpoints for prostate cancer-specific survival may require less time to complete. Ray et al. (p. 228) used data from the Radiation Therapy and Oncology Group 92-02 randomized trial and Prentice's four criteria for surrogacy to evaluate two potential surrogate endpoints for prostate cancer-specific sur-vival—distant metastasis and general clinical treatment failure. At 3 years, both distant metastasis and general clinical treatment failure were consistent with all four of Prentice's criteria for being surrogate endpoints for prostate cancer-specific survival at 10 years. At 5 years, prostate cancer-specific survival was not statistically significantly different between treatment arms of the randomized trial, so . . . [Full Text of this Article]

Dependence Receptor Signalling in Non-Small Cell Lung Cancer

Maintenance with Rituximab for Follicular Lymphoma

Aspirin for Chemoprevention for Colorectal Adenomas

NSAIDs After Aspirin Treatment and Risk of Colorectal Adenoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials
Liat Vidal, Anat Gafter-Gvili, Leonard Leibovici, Martin Dreyling, Michele Ghielmini, Shu-Fang Hsu Schmitz, Amos Cohen, and Ofer Shpilberg
J Natl Cancer Inst 2009 101: 248-255. [Abstract] [Full Text] [PDF]

Nonsteroidal Anti-inflammatory Drug Use After 3 Years of Aspirin Use and Colorectal Adenoma Risk: Observational Follow-up of a Randomized Study
Maria V. Grau, Robert S. Sandler, Gail McKeown-Eyssen, Robert S. Bresalier, Robert W. Haile, Elizabeth L. Barry, Dennis J. Ahnen, Jiang Gui, Robert W. Summers, and John A. Baron
J Natl Cancer Inst 2009 101: 267-276. [Abstract] [Full Text] [PDF]

Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials
Bernard F. Cole, Richard F. Logan, Susan Halabi, Robert Benamouzig, Robert S. Sandler, Matthew J. Grainge, Stanislas Chaussade, and John A. Baron
J Natl Cancer Inst 2009 101: 256-266. [Abstract] [Full Text] [PDF]

Potential Surrogate Endpoints for Prostate Cancer Survival: Analysis of a Phase III Randomized Trial
Michael E. Ray, Kyounghwa Bae, Maha H. A. Hussain, Gerald E. Hanks, William U. Shipley, and Howard M. Sandler
J Natl Cancer Inst 2009 101: 228-236. [Abstract] [Full Text] [PDF]

Interference With Netrin-1 and Tumor Cell Death in Non–Small Cell Lung Cancer
Céline Delloye-Bourgeois, Elisabeth Brambilla, Marie-May Coissieux, Céline Guenebeaud, Rémy Pedeux, Virginie Firlej, Florence Cabon, Christian Brambilla, Patrick Mehlen, and Agnès Bernet
J Natl Cancer Inst 2009 101: 237-247. [Abstract] [Full Text] [PDF]

To Die or Not to Die, That's the Question—And the Answer May Depend on Netrin-1
Michael P. Schön and Margarete Schön
J Natl Cancer Inst 2009 101: 217-219. [Extract] [Full Text] [PDF]

Surrogate and Mediating Endpoints: Current Status and Future Directions
Ross L. Prentice
J Natl Cancer Inst 2009 101: 216-217. [Extract] [Full Text] [PDF]